Titration, explained: why GLP-1 doses start low and climb slowly
The slow dose ramp is not caution for its own sake. It is the single biggest factor in whether treatment stays tolerable.
By The Vive Team
August 2026 · 6 min read
Every GLP-1 medicine starts at a dose lower than the one you will likely end up on, and climbs in steps over weeks. Patients often read this as bureaucratic caution. It is not — it is the mechanism by which the medicine stays liveable.
What titration is actually managing
The starting dose of a GLP-1 is generally not the dose that produces the full clinical effect. It exists to let your body adjust to the signal.
The dominant side effects of this drug class are gastrointestinal: nausea, vomiting, diarrhoea, constipation, abdominal discomfort. These are strongly related to how quickly the dose rises. Escalate slowly and most people move through them. Escalate fast and the same person may find the medicine intolerable at a dose they could have handled comfortably if they had arrived there gradually.
So titration is primarily managing tolerability, not efficacy. The destination is similar; the route determines whether you make it there.
What a schedule looks like in practice
The exact ladder differs by medicine and is set out in each product’s prescribing information. The shape is consistent, though:
- Begin at a low starting dose for a set number of weeks.
- Step up only after that interval, if the current step is being tolerated.
- Hold at a step longer if side effects need time to settle.
- Arrive at a maintenance dose, which may be lower than the maximum.
That last point gets overlooked. The maximum labelled dose is not a target everyone should reach. Plenty of people do well at an intermediate dose, and there is no clinical prize for climbing higher.
You can see an illustrative schedule in our semaglutide dosage planner — an educational tool, not a prescription.
Why skipping steps is not safe, even when you feel fine
Feeling well on your current dose is exactly what the schedule is designed to produce. It is evidence the approach is working, not evidence you can shortcut it.
Increasing a dose ahead of schedule, doubling up after a missed dose, or adjusting on your own reliably produces one outcome: the side effects the ladder exists to avoid. If a dose feels wrong in either direction, that is a conversation with your care team, not a solo adjustment.
When the schedule should change
Titration is a plan, not a contract. Your physician may hold you at a step, step you back down, or extend an interval based on how you are actually doing. If side effects are not settling, or you are struggling to eat or stay hydrated, say so — see when to call your doctor for what warrants a message versus urgent care.
Practical guidance on getting through the adjustment period is in managing side effects.
Dosing decisions belong to your prescribing physician. Results and tolerability vary from person to person. Read the Important Safety Information.
// References
- 1.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. View study →
- 2.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. View study →
- 3.Product prescribing information for GLP-1 receptor agonists (dose-escalation schedules; gastrointestinal adverse reactions).
Provided for education only. Trial averages describe study populations, not any individual’s expected result. This is not medical advice — GLP-1 medication is prescription-only and outcomes vary.
Medically reviewed by Vive’s licensed physicians. Meet the clinicians →
Curious what’s right for you?
Take the 3-min quiz →